Loading...
•
Dec 31, 2022
Amphastar Q4 2022 Earnings Report
Reported net revenues of $135.0 million, GAAP net income of $33.9 million, or $0.66 per share, and adjusted non-GAAP net income of $37.6 million, or $0.73 per share.
Key Takeaways
Amphastar Pharmaceuticals reported its strongest quarter yet, with net revenues of $135.0 million, GAAP net income of $33.9 million, or $0.66 per share, and adjusted non-GAAP net income of $37.6 million, or $0.73 per share, driven by sales of epinephrine, Primatene MIST®, glucagon, and other finished pharmaceutical products.
Net revenues for the fourth quarter were $135.0 million.
GAAP net income for the fourth quarter was $33.9 million, or $0.66 per share.
Adjusted non-GAAP net income for the fourth quarter was $37.6 million, or $0.73 per share.
The company anticipates launching multiple new products to continue driving growth in 2023.
Revenue by Segment
Forward Guidance
Looking ahead to 2023, the company anticipates launching multiple new products to continue driving growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...